生物制剂与内镜鼻窦手术治疗鼻息肉的疗效及反应预测因素:系统综述
该系统综述纳入13项试验(n=3775)的21篇发表文献,间接比较生物制剂与内镜鼻窦手术(ESS)治疗成人慢性鼻窦炎伴鼻息肉(CRSwNP)的疗效。结果显示,dupilumab和tezepelumab的效应量最大,ESS疗效因试验和随访时间而异,不同疗法的疗效预测因素不同。
要点
- dupilumab和tezepelumab在生物制剂中效应量最大,但跨试验间接比较需谨慎。
- ESS的SNOT-22改善在MACRO试验6个月为-21.9,PolypESS 12个月为-4.9。
- dupilumab的预测因素包括血嗜酸性粒细胞计数、NSAID加重呼吸疾病和既往ESS。
核心结论
- ESS和生物制剂均提供有临床意义的获益。
- 在生物制剂中,dupilumab和tezepelumab显示出最大的效应量,但跨试验的基线严重度、随访和对照差异限制间接比较。
- 需要头对头试验和标准化亚组分析来指导治疗选择。
研究设计与样本
- 系统综述纳入10项3期安慰剂对照生物制剂RCT、2项实用性ESS试验和1项头对头生物制剂试验,共13项试验(n=3775),来自21篇发表文献。
主要发现
- 间接比较显示,tezepelumab的SNOT-22改善为-27.4、NPS改善为-2.1;dupilumab的SNOT-22改善为-17至-21、NPS改善为-1.7至-2.1。
- mepolizumab和omalizumab显示中等效应(SNOT-22:-10.6至-16.5)。
- benralizumab改善NPS但不改善SNOT-22,depemokimab的改善低于临床可辨别差异。
- ESS效应因试验和随访而异:MACRO试验6个月SNOT-22为-21.9,PolypESS试验12个月为-4.9。
- 预测因素因疗法而异:dupilumab为血嗜酸性粒细胞计数、NSAID加重呼吸疾病和既往ESS;benralizumab为哮喘;ESS为基线严重度;tezepelumab和omalizumab无效应修饰。
关键数值与推荐
- tezepelumab:SNOT-22 -27.4,NPS -2.1;dupilumab:SNOT-22 -17至-21,NPS -1.7至-2.1;mepolizumab和omalizumab:SNOT-22 -10.6至-16.5。
- ESS:MACRO试验6个月SNOT-22 -21.9,PolypESS试验12个月SNOT-22 -4.9。
临床怎么用
- 对于CRSwNP患者,dupilumab和tezepelumab可能提供更大的效应量,但需考虑跨试验差异。
- 选择生物制剂时可参考预测因素:dupilumab考虑血嗜酸性粒细胞计数、NSAID加重呼吸疾病和既往ESS;benralizumab考虑哮喘。
- ESS的疗效因试验和随访时间而异,需个体化评估。
局限性
- 跨试验基线严重度、随访和对照的差异限制间接比较。
- 缺乏头对头试验和标准化亚组分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biologics and endoscopic sinus surgery (ESS) treat refractory chronic rhinosinusitis with nasal polyposis (CRSwNP), but direct comparisons are lacking. We synthesized efficacy and subgroup data across randomized controlled trials (RCTs) of biologics and ESS. METHODS: PubMed was searched through December 2025 for RCTs and subgroup analyses of biologics or ESS for adult CRSwNP. Included were ten Phase-3 placebo-controlled biologic RCTs, two pragmatic ESS trials, and one head-to-head biologic trial. 22-Item Sino-Nasal Outcome Test (SNOT-22) and nasal polyp score (NPS) effect sizes and subgroup interactions were extracted. RESULTS: A total of 13 trials (n = 3775) from 21 publications were included. By indirect comparison, tezepelumab and dupilumab produced the largest improvements (tezepelumab: SNOT-22: -27.4; NPS: -2.1; dupilumab: SNOT-22: -17 to -21; NPS: -1.7 to -2.1), while mepolizumab and omalizumab showed intermediate effects (SNOT-22: -10.6 to -16.5); benralizumab improved NPS but not SNOT-22, and depemokimab showed improvement below clinically discernible differences. ESS effects varied by trial and follow-up (SNOT-22: -21.9 at 6 months in MACRO vs. -4.9 at 12 months in PolypESS). Predictors of improvement differed across therapies (blood eosinophil count, NSAID-exacerbated respiratory disease, and prior ESS for dupilumab; asthma for benralizumab; baseline severity for ESS), while tezepelumab and omalizumab showed consistent efficacy without effect modification. CONCLUSIONS: ESS and biologics provide clinically meaningful benefit. Among biologics, dupilumab and tezepelumab demonstrated the largest effect sizes, though cross-trial differences in baseline severity, follow-up, and comparators limit indirect comparisons. Head-to-head trials and standardized subgroup analyses are needed to guide treatment selection.
引用
- Chakravorty A, Lin ME, Lubner R, et al. Efficacy and Predictors of Response to Biologic Therapy and Endoscopic Sinus Surgery in Patients With Nasal Polyps: A Systematic Review. Int Forum Allergy Rhinol. 2026. PMID: 42716513. doi:10.1002/alr.70264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。